Hengrui Pharma, GSK enter licensing deal worth up to $12bn
GSK will obtain a global license to Hengrui Pharma’s potential PDE3/4 programme, HRS-9821, except in mainland China, Hong Kong, Macau and Taiwan.
News
Krystal Biotech’s Vyjuvek authorised in Japan to treat DEB
Ipsen secures EC approval for Cabometyx in neuroendocrine tumours
Matchpoint, Novartis partner for inflammatory disease treatments
US FDA extends review period for GSK’s Blenrep in multiple myeloma
EC approves Roche’s Itovebi-based regimen to treat breast cancer
Sanofi to acquire UK biotechnology firm Vicebio for up to $1.6bn
AstraZeneca to invest $50bn in US by 2030, boosting medicine manufacturing
